Company intelligence / Profile preview

Syntax Bio

Chicago, Illinois, United States

Ownership: Private
Employees: ~25
Development stage: Other

Overview

Preclinical synthetic biology company offering a CRISPR-based Cellgorithm platform that programs endogenous gene activity to accelerate and control stem cell differentiation, enabling faster and more reproducible generation of therapeutic-grade cells for multiple indications, primarily through discovery partnerships rather than its own clinical-stage assets.[1][3][4][5][6]

Therapeutic areas: HematologyEndocrinologyCardiovascularNeurologyRheumatologyOphthalmology
Modalities: Cell therapyGene therapyCRISPR-based therapy
Industry: Non-Drug Biotech

Partnerships

Breakthrough T1D (pancreatic beta cell program for type 1 diabetes)[3][4][6]Multiple unnamed biopharmaceutical partners using Cellgorithm-based differentiation for cell therapy R&D[3][5][6]

Beyond the preview

Go deeper on Syntax Bio.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Syntax Bio.

Explore the full profile